Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/40742
Title: | Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association and the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension | Authors: | Anker, Stefan D. Usman, Muhammad Shariq Anker, Markus S. Butler, Javed Boehm, Michael Abraham, William T. Adamo, Marianna Chopra, Vijay K. Cicoira, Mariantonietta Cosentino, Francesco Filippatos, Gerasimos Jankowska, Ewa A. Lund, Lars H. Moura, Brenda MULLENS, Wilfried Pieske, Burkert Ponikowski, Piotr Gonzalez-Juanatey, Jose R. Rakisheva, Amina Savarese, Gianluigi Seferovic, Petar Teerlink, John R. Tschoepe, Carsten Volterrani, Maurizio von Haehling, Stephan Zhang, Jian Zhang , Yuhui Bauersachs, Johann Landmesser, Ulf Zieroth, Shelley Tsioufis, Konstantinos Bayes-Genis, Antoni Chioncel, Ovidiu Andreotti, Felicita Agabiti-Rosei, Enrico Merino, Jose L. Metra, Marco Coats, Andrew J. S. Rosano, Giuseppe M. C. |
Issue Date: | 2023 | Publisher: | WILEY | Source: | EUROPEAN JOURNAL OF HEART FAILURE, 25 (7) , p. 936 -955 | Abstract: | Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous clinical syndrome affected in its development and progression by many comorbidities. The left ventricular diastolic dysfunction may be a manifestation of various combinations of cardiovascular, metabolic, pulmonary, renal, and geriatric conditions. Thus, in addition to treatment with sodium-glucose cotransporter 2 inhibitors in all patients, the most effective method of improving clinical outcomes may be therapy tailored to each patient's clinical profile. To better outline a phenotype-based approach for the treatment of HFpEF, in this joint position paper, the Heart Failure Association of the European Society of Cardiology, the European Heart Rhythm Association and the European Hypertension Society, have developed an algorithm to identify the most common HFpEF phenotypes and identify the evidence-based treatment strategy for each, while taking into account the complexities of multiple comorbidities and polypharmacy. | Notes: | Anker, SD (corresponding author), Berlin Inst Hlth Ctr Regenerat Therapies BCRT, Dept Cardiol, Deutsch Herzzentrum Charite Campus CVK, Berlin, Germany.; Anker, SD (corresponding author), Charite, German Ctr Cardiovasc Res DZHK, Partner Site Berlin, Berlin, Germany. s.anker@cachexia.de |
Keywords: | Heart failure;Heart failure with preserved ejection fraction;Phenotype | Document URI: | http://hdl.handle.net/1942/40742 | ISSN: | 1388-9842 | e-ISSN: | 1879-0844 | DOI: | 10.1002/ejhf.2894 | ISI #: | 001031398300001 | Rights: | 2023 European Society of Cardiology. Open access | Category: | A2 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association,.pdf | Published version | 692.29 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.